Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CBIO
- Price
- 10.97
- Stock movement up
- +0.03 (0.27%)
- Company name
- Crescent Biopharma, Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 213.91M
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2026-01-08
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CBIO does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 10.76 |
| Daily high | 11.09 |
| Daily low | 10.57 |
| Daily Volume | 105K |
| All-time high | 15.31 |
| 1y analyst estimate | 22.00 |
| Beta | - |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | 13 Jan 2023 |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| CBIO | S&P500 | |
| Current price drop from All-time high | -28.35% | -0.33% |
| Highest price drop | -28.54% | -19.00% |
| Date of highest drop | 7 Jan 2026 | 8 Apr 2025 |
| Avg drop from high | -9.01% | -2.54% |
| Avg time to new high | 8 days | 6 days |
| Max time to new high | 23 days | 89 days |
COMPANY DETAILS
Marketcap
213.91M
Marketcap category
Small-cap
Description
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
Employees
41
Investor relations
-
SEC filings
CEO
Nassim Usman
Country
USA
City
South San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner